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ABSTRACT
Background. The randomized EORTC 10981-22023
AMAROS trial investigates whether breast cancer patients
with a tumor-positive sentinel node biopsy (SNB) are best
treated with an axillary lymph node dissection (ALND) or
axillaryradiotherapy(ART).Theaimofthecurrentsubstudy
was to evaluate the identiﬁcation rate and the nodal
involvement.
Methods. The ﬁrst 2,000 patients participating in the
AMAROS trial were evaluated. Associations between the
identiﬁcation rate and technical, patient-, and tumor-related
factors were evaluated. The outcome of the SNB procedure
and potential further nodal involvement was assessed.
Results. In 65 patients, the sentinel node could not be
identiﬁed. As a result, the sentinel node identiﬁcation rate
was 97% (1,888 of 1,953). Variables affecting the success
rate were age, pathological tumor size, histology, year of
accrual, and method of detection. The SNB results of 65%
of the patients (n = 1,220) were negative and the patients
underwent no further axillary treatment. The SNB results
were positive in 34% of the patients (n = 647), includ-
ing macrometastases (n = 409, 63%), micrometastases
(n = 161, 25%), and isolated tumor cells (n = 77, 12%).
Further nodal involvement in patients with macrometasta-
ses, micrometastases, and isolated tumor cells undergoing
an ALND was 41, 18, and 18%, respectively.
Conclusions. With a 97% detection rate in this prospec-
tive international multicenter study, the SNB procedure is
highly effective, especially when the combined method is
used. Further nodal involvement in patients with microm-
etastases and isolated tumor cells in the sentinel node was
similar—both were 18%.
The concept of sentinel node biopsy (SNB) is based on
an orderly pattern of lymphatic drainage from the primary
tumor to regional lymph node basins.
1 The ﬁrst lymph node
to which a tumor drains, the sentinel node, is detected with
the aid of blue dye and/or a radioactive tracer and subse-
quently removed. The pathological status of the sentinel
node is used to decide whether an axillary lymph node
dissection (ALND) should be performed. Patients with a
tumor-negative sentinel node can be spared a completion
ALND and the associated side effects. In 1994, Giuliano
et al. ﬁrst reported the SNB procedure in breast cancer.
2 The
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DOI 10.1245/s10434-010-0945-zSNB procedure was followed by routine ALND in the
learningphase.In this period, the median false-negative rate
of the SNB procedure was 7%.
3 At present, the sentinel
node procedure is the standard treatment in patients with a
clinically negative axilla. The axillary recurrence rate in
patients with a negative sentinel node is low, 0.3% after a
median of 34 months.
4 Nevertheless, whether omitting an
ALND in patients with tumor-negative sentinel nodes will
affect the survival is still subject of research in the National
Surgical Adjuvant Breast and Bowel Project B-32 trial.
5
Patients with a tumor-positive sentinel node are gener-
ally treated with an ALND. Severe side effects of ALND
include lymph edema and decreased arm and shoulder
function and are observed in 5% to 39% of the patients
after axillary clearance.
6–8 In 2001, the European Organi-
zation of Research and Treatment of Cancer (EORTC)
initiated a trial to evaluate the role of axillary radiation.
The EORTC 10981 AMAROS (After Mapping of the
Axilla, Radiotherapy or Surgery?) trial is a phase III study
comparing ALND with axillary radiotherapy (ART) in
patients with a tumor-positive sentinel node.
9 The main
objective of the trial is to prove equivalent locoregional
control and reduced morbidity for ART. A secondary aim
is to assess the survival in patients with tumor-negative
sentinel node without additional axillary clearance.
Therefore, patients with a tumor-negative sentinel node are
also included in the AMAROS trial. The AMAROS trial is
ongoing. The accrual of the required 4,767 patients is
expected to be ﬁnalized in the year 2010.
The aim of the current substudy was to analyze the
technical aspects and outcome of the SNB procedure in the
ﬁrst 2,000 patients, mainly to control for validity of future
trial results. We analyzed the identiﬁcation rate of the SNB
procedure and the association between the identiﬁcation
rate and several technical, clinical, and pathological vari-
ables. With regard to the outcome of the SNB procedure,
research was focused on the relation between the size of the
sentinel node metastases and the further nodal involvement.
PATIENTS AND METHODS
After obtaining permission from the EORTC Indepen-
dent Data Monitoring Committee, the ﬁrst 2,000 patients
with operable unifocal invasive breast cancer (5–30 mm)
and clinically negative lymph nodes enrolled onto the
AMAROS trial were analyzed. The study design of the
AMAROS trial is shown in Fig. 1. Patients were not
admitted to the AMAROS trial if any of the following
criteria were present: (1) metastatic disease, (2) previous
treatment of the axilla by surgery or radiotherapy, (3)
previous treatment of cancer, except basal-cell carcinoma
of the skin and in-situ carcinoma of the cervix, or (4)
pregnancy. Between 2001 and 2005, a total of 2,000
patients were entered in the AMAROS trial from 26
institutions in Europe. All institutions have been site visited
as part of the surgical quality assurance.
Before the SNB procedure, patients were randomized
between ALND and ART. This allowed the application of
breast surgery and axillary surgery simultaneously when
positive sentinel nodes were found by frozen section. Of
the ﬁrst 2,000 patients, 41 patients were ineligible as a
result of patient refusal or because they did not meet the
inclusion criteria, and in 6 patients, the SNB procedure was
not performed (Fig. 2). Hence, 1,953 patients were eligible
for this substudy, and data from these patients form the
body of this report. Randomization was accomplished
centrally by the EORTC headquarters, and patients were
stratiﬁed according to institution. The AMAROS trial was
approved by the institutional ethical committees, and
informed consent was obtained from all patients. The
indications to offer systemic therapy were not ﬁxed in the
protocol. The actual chemotherapies and endocrine thera-
pies were provided according to local guidelines.
Surgery
All participating surgeons had to have previously per-
formed a minimum of 30 prequalifying cases of the SNB
0.5–3.0cm invasive breast cancer
clinically negative axilla
Randomization:
ALND vs. axillary radiotherapy
Sentinel node biopsy procedure
Sentinel node
negative
Follow up
Sentinel node
positive
ALND Axillary
radiotherapy
Quality of life
questionnaire
(1, 2, 3, 5, 10 years)
Shoulder function
(1, 3, 5, 10 years)
Quality of life
questionnaire
(1, 2, 3, 5, 10 years)
Shoulder function
(1, 3, 5, 10 years)
FIG. 1 Study design. Patients with clinically negative lymph nodes
and tumors of \3 cm are randomized between ALND and axillary
radiotherapy before the sentinel node biopsy procedure. In sentinel
node–negative patients, no further axillary treatment is provided
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ticipate in the trial. In 1,744 patients, the SNB procedure
was performed by the combined method of blue dye and
isotope with intraoperatively detection with a gamma
probe. A minority of SNB procedures were performed with
isotope (n = 181) or blue dye (n = 19) only. Lympho-
scintigrams were recommended, although not mandatory.
Radioactive and blue-stained nodes were removed, and if
present, nonsentinel nodes that were suspicious for meta-
static cancer on palpation but that were not radioactive or
blue were also removed. Subsequently, mastectomy or
breast-conserving surgery was carried out. Patients with
tumor-positive sentinel nodes who were allocated to the
ALND arm underwent a level I and II ALND within
12 weeks. In that case, removal of at least eight lymph
nodes was mandatory.
Radiotherapy
Sentinel node–positive patients allocated to the ART
arm were irradiated within 12 weeks after surgery. All
three levels of the axilla together with the medial part of
the supraclavicular fossa were considered clinical the target
volume. The prescribed dose to the axilla as a whole was
50 Gy in 25 fractions of 2 Gy in 5 weeks. All institutions
documented their techniques for axillary irradiation on a
dummy run that was evaluated by the radiotherapy quality
assurance team before their participation was allowed.
10
Postoperative axillary irradiation in patients undergoing
ALND was allowed in patients with four or more tumor-
positive nodes (pN2 or pN3) and was applied according to
institutional protocols.
Pathology
As a minimal requirement, three histological levels
(500-lm distance) for each sentinel node were examined.
On each level, two parallel sections were performed, one
for immunohistochemistry and one for hematoxylin and
eosin staining. Immunohistochemical staining was per-
formed for markers containing at least cytokeratin 8 and 18
(e.g., CAM 5.2). Immunohistochemical staining was
required only when hematoxylin and eosin staining was
negative. The sentinel node was considered tumor positive
if any tumor deposit in the node or in the afferent or
efferent lymph vessels was found. Tumor deposits were
categorized as isolated tumor cells (\0.2 mm), microme-
tastases (0.2–2 mm), or macrometastases ([2 mm).
Statistical Analysis
Associations between the identiﬁcation rate and patient
and tumor related factors were evaluated by Cochran–
Mantel–Haenszel (v
2) type tests for overall association. All
P values were two tailed, with P = 0.05 or lower consid-
ered signiﬁcant.
RESULTS
The patient and tumor characteristics of the 1,953 eli-
gible patients in whom a SNB procedure was performed
are shown in Table 1. The median age was 57 years (range
24–87 years), and most patients had ductal invasive car-
cinoma. The tumor size at pathology was mostly\20 mm;
pT1 and pT2 tumors were seen in 74 and 24%,
respectively.
Identiﬁcation Rate
In 65 patients, the sentinel node could not be identiﬁed.
Thus, the sentinel node identiﬁcation rate was 97% (1,888
of 1,953). Variables affecting the success rate were age,
pathological tumor size, histology, year of accrual, and
method of detection (Table 2). The success rate was higher
in younger patients. In patients with pT3 tumors, the
identiﬁcation rate was lower compared to patients with pT1
tumors. In patients with lobular and ductal carcinomas, the
success rate was high compared to other types of histology
Total of patients
(n = 2000)
Ineligible patients (n = 41)
SNB not done (n = 6)
SNB not identified (n = 65)
Eligible patients
(n = 1953)
Eligible + SN indentified
(n = 1888)
SNB
negative
(n = 1220)
SNB
positive
(n = 647)
Only
non-axillary
SN positive
(n = 10)
Only
non-SN
positive
(n = 11)
ITC
(n = 77)
Micro
(n = 161)
Macro
(n = 409)
FIG. 2 Patient ﬂow in the EORTC AMAROS trial regarding the
identiﬁcation and results of the SNB procedure. SN sentinel node;
Macro macrometastases ([2 mm); Micro micrometastases (0.2–
2 mm); ITC isolated tumor cells (\0.2 mm)
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identiﬁcation rate increased within the time period of the
study, although the detection was high in the ﬁrst year of
the study. With the combination of blue dye and radioac-
tive tracers, a higher identiﬁcation rate was achieved
compared to one of these tracers only. In case of nonvi-
sualization by lymphoscintigraphy, 77% of the SNB
procedures were still performed successfully.
Drainage to the internal mammary chain was observed
in 11% of the patients (198 of 1,778) (Fig. 3). The treat-
ment of the internal mammary chain differed by institution.
In half of the patients with drainage to the internal mam-
mary chain, these nodes were removed.
Outcome of Sentinel Node Procedure
Sixty-ﬁve percent of patients (n = 1,220) were sentinel
node negative and underwent no further axillary treatment.
The sentinel node was positive in 34% (n = 647). In this
group, 409 patients (63%) had macrometastases, 161
patients (25%) had micrometastases, and 77 patients (12%)
had isolated tumor cells. Ten patients (0.5%) had positive
sentinel nodes only in an extra-axillary region, i.e., internal
mammary chain or supraclavicular. In these patients, no
further axillary treatment was performed. In 357 (19%) of
1,888 patients, nonsentinel nodes were removed (nonblue
or nonradioactive lymph nodes) during the SNB procedure.
These nonsentinel nodes were tumor positive in 12%
(n = 44). Predictive variables for tumor-positive nonsen-
tinel nodes were tumor size (P\0.001) and tumor grade
(P\0.001). Nonsentinel nodes were more frequently
tumor positive in large and high-grade tumors. In 11
patients (3%), these nonsentinel nodes were the only
tumor-positive sentinel nodes. Four of these patients had
lack of drainage seen on preoperative lymphoscintigraphy.
These SNB procedures can actually be considered falsely
negative. Because axillary clearance is omitted in sentinel
node–negative patients, the actual false-negative rate in
this study will remain unknown.
We did not separately collect data about the outcome of
the sentinel nodes in the internal mammary chain in
patients in whom these were removed.
Further Nodal Involvement
The further nodal involvement could only be determined
in the group of patients randomized to the ALND arm
(Table 3). Forty-one percent of the patients with ma-
crometastases had additional nodal involvement. Further
nodal involvement was 18% in both the patients with mi-
crometastases and the patients with isolated tumor cells.
More than four additional lymph nodes were tumor posi-
tive in the patients with macrometastases, micrometastases,
and isolated tumor cells in 9, 6, and 3%, respectively. In the
patients with micrometastases or isolated tumor cells in the
sentinel node and more than four tumor-positive additional
lymph nodes, these consisted of more than four macrom-
etastases in all patients except one.
DISCUSSION
In this prospective multicenter study, the sentinel node
identiﬁcation rate was 97%. Lymphatic mapping with the
sentinel node procedure was ﬁrst reported in breast cancer in
1994 and is therefore a relatively young procedure. The
patients described in this study were included in the period
from2001and2004,andwerethusintherelativelyearlydays
of the general introduction of this procedure. Nevertheless,
the success rate was high. The identiﬁcation rate was inﬂu-
enced by several variables that we will discuss separately.
The reduced identiﬁcation rate in older patients is con-
sistently reported.
11–13 The increased fatty tissue in the
breast in elderly patients might cause an decreased lym-
phatic ﬂow.
14 It is also suggested that the replacement of
lymph nodes by fatty tissue decreases the capacity of
lymph nodes to retain the radioactive colloid.
15
TABLE 1 Patient and tumor characteristics of eligible patients
(n = 1,953)
Characteristic Value
Age (year)
Median 57
Range 24–87
Menopausal status, n (%)
Premenopausal 543 (28%)
Perimenopausal 113 (6%)
Postmenopausal 1,193 (61%)
Unknown 104 (5%)
Pathological tumor size, n (%)
T1 1,454 (74%)
T2 465 (24%)
T3 13 (1%)
Missing 21 (1%)
Histology, n (%)
Ductal 1,416 (73%)
Lobular 220 (11%)
Other 304 (16%)
Missing 13 (1%)
Grade, n (%)
I 548 (28%)
II 842 (43%)
III 493 (25%)
Missing 70 (4%)
Technical Aspects and Outcome SNB 1857Tumor size was also associated with the detection rate,
showing a low identiﬁcation rate in tumors[5 cm in size.
It must be noted that only 13 patients in this study had
tumors of[5 cm. Patients with large tumors have a greater
risk of extensive axillary tumor burden, which decreases
the lymphoscintigraphic visualization.
16,17 Patients with
more than four tumor-positive lymph nodes have nonvi-
sualization in [50%.
18 Performance of ultrasound-guided
ﬁne-needle aspiration before the SNB procedure will
identify at least some of these patients and thus increase the
identiﬁcation rate.
In this study, the identiﬁcation rate was slightly lower in
patients with other than ductal and lobular carcinomas.
This group includes mainly tubular, mucinous, and mixed
ductolobular tumors. Because of the heterogeneity of this
group, this ﬁnding is difﬁcult to explain. Others have not
found a correlation with histology.
19,20
The association between method of detection and the
sentinel node identiﬁcation is notable, showing a higher
detection rate with the combined method (radioactive tra-
cer and blue dye). With blue dye, the lymphatic channel
can be identiﬁed until it enters and stains the ﬁrst node. The
value of the gamma detection probe is that the location of
the node can be determined through the intact skin, and the
sentinel can be identiﬁed once the lymphatic channel is
accidentally damaged. Relying on the gamma detection
probe only and omitting blue dye leads to a situation where
relevant nodes are left behind, because 5–17% of the
sentinel nodes are only blue.
5,21,22 Some investigators,
however, still use only one of the detection methods. On
the basis of our results, which have been conﬁrmed by
others, we recommend the use of the combined
method.
3,11,13
The year of accrual also inﬂuenced the identiﬁcation
rate and reﬂected a learning curve, although surgeons
TABLE 2 Variables affecting the SNB identiﬁcation rate
Variable Not
identiﬁed
(n = 65),
n (%)
Identiﬁed
(n = 1,888),
n (%)
P
Age (year) 0.002
\30 0 (0) 5 (100)
30–49 9 (2) 481 (98)
50–69 37 (3) 1,163 (97)
C70 19 (7) 239 (93)
Pathological tumor size (cm) \0.001
B1 14 (3) 411 (97)
1–2 30 (3) 999 (97)
2–3 6 (2) 401 (98)
3–5 3 (5) 55 (95)
[5 3 (23) 10 (77)
Histology 0.009
Invasive ductal 38 (3) 1,378 (97)
Invasive lobular 2 (1) 218 (99)
Other 16 (5) 288 (95)
Year of accrual 0.043
2001 2 (1) 151 (99)
2002 20 (6) 325 (94)
2003 12 (3) 467 (97)
2004 19 (3) 530 (97)
2005 12 (3) 415 (97)
Method SNB \0.001
Blue dye only 2 (11) 17 (90)
Radioactive tracer only 18 (10) 163 (90)
Blue dye and radioactive
tracer
36 (2) 1,708 (98)
Lymphoscintigram NA
Nonvisualization 29 (23) 99 (77)
SNB sentinal node biopsy; NA not applicable; NS not signiﬁcant
Drainage on lymphoscintogram
(n = 1778)
Ipsilateral axilla
(n = 1513) 85%
Extra-axillar
(n = 60) 3%
Both
(n = 205) 12%
Other
(n = 11)
IMC
(n = 49)
Axilla and Other
(n = 56)
Axilla and IMC
(n = 149)
IMC sentinel
node not removed
(n = 23) 47%
IMC sentinel
node removed
(n = 26) 53%
IMC sentinel
node not removed
(n = 73) 49%
IMC sentinel
node removed
(n = 76) 51%
FIG. 3 Drainage to the internal
mammary chain seen on
lymphoscintigraphy and the subsequent
surgical removal. IMC internal
mammary chain
1858 M. E. Straver et al.participating in this trial were past their learning period of
30 SNB procedures with a completion axillary clearance.
Remarkably, the detection rate was lowest in 2002 and not
at the start of the study in 2001. This might be explained by
the relatively high number of patients accrued by highly
experienced academic institutes at the beginning of the
AMAROS trial.
In this study, lymphoscintigraphy did not visualize
sentinel nodes in a small number of patients. Despite the
nonvisualization, the sentinel node could still be identiﬁed
in 77% of these patients, particularly by blue dye. This
suggests that SNB procedure ought to be pursued in these
patients, and that nonvisualization is not an absolute indi-
cation for ALND.
Finally, we observed that in 3% of the patients in whom
nonsentinel nodes were removed, these nonsentinel nodes
were the only tumor-positive nodes. In these patients, the
SNB procedure can be considered as falsely negative.
Extensive tumor burden may obstruct the lymph ﬂow and
thus lead to falsely negative sentinel nodes. This ﬁnding
emphasizes the importance of palpation after removing the
sentinel node. The false-negative rate could also be
diminished by performing preoperative axillary ultrasound.
In the patient population of the AMAROS trial—that is,
patients with a clinically negative axilla and breast tumor of
\3 cm—34% of the patients had a tumor-positive sentinel
node. Isolated tumor cells within the sentinel node were
classiﬁed as having node-positive disease at this time,
according to the previous edition (5th edition) of the
American Joint Committee on Cancer staging manual.
23
Yet in the current substudy of this prospective clinical trial,
we were able to assess the further nodal involvement in
macrometastases, micrometastases, and isolated tumor
cells separately. Further nodal involvement was seen in
18% of the patients with both micrometastases (15 of 84)
and isolated tumor cells (6 of 33), whereas extensive nodal
involvement was slightly higher in patients with microm-
etastases. In the current staging classiﬁcation systems,
isolated tumor cells are classiﬁed as node-negative
(pN0(i?)) disease.
24,25 Since 2008, in the AMAROS trial,
isolated tumor cells are also considered to be sentinel node
negative and do not require further axillary treatment.
In the most recent meta-analysis, the overall pooled risk
for additional nodal involvement in patients with isolated
tumors cells was 12.3% (95% conﬁdence interval 9.5–
15.7).
26 Omitting ALND is probably acceptable for most
patients whose sentinel node contains isolated tumor cells,
especially given a marginally lower false-negative rate of
7% of the SNB procedure.
3 Additional microscopic axil-
lary metastases might be eradicated by adjuvant
radiotherapy to the breast, including the caudal half of the
axilla, or by adjuvant chemotherapy or endocrine therapy.
These hypotheses are reﬂected by a low axillary recurrence
rate in sentinel node–positive patients treated with a SNB
procedure only (i.e., without axillary clearance).
27–32
The retrospective Dutch MIRROR trial recently showed
that omission of further axillary treatment in patients with
micrometastases resulted in a far higher 5-year axillary
recurrence rate (1.2 vs. 6.2%, hazard ratio 4.45; 95%
conﬁdence interval 1.46–13.54).
33 The International Breast
Cancer Study Group trial IBCSG-23-01 is currently
addressing whether differences in survival exist between
patients with micrometastases who have a SNB procedure
compared with ALND.
34 However, the size of the sentinel
node metastases is not the only predictor for further nodal
involvement. Increased tumor size, more than one positive
sentinel lymph node, lymphovascular invasion in the pri-
mary tumor, and lobular histology also have statistically
signiﬁcant predictive value.
35 Several nomograms and
models including these variables have been established to
estimate the risk of further nodal involvement and might be
used to select those patients with micrometastases and
isolated tumor cells who may beneﬁt from axillary treat-
ment and those who can be safely spared axillary
clearance.
36 Further studies addressing which patients with
microscopic metastases in the sentinel node can be safely
withhold axillary treatment are warranted.
In conclusion, this study indicates that with a 97%
detection rate in this prospective international multicenter
study the sentinel node procedure is highly effective. The
success rate is inﬂuenced by the method of the SNB pro-
cedure and by several patient and tumor characteristics. In
TABLE 3 Further nodal involvement in ALND specimen
a
Characteristic n %
Macro (n = 200)
No further involvement 117 59
1–3 nodes 65 32
4–9 nodes 10 5
[9 nodes 8 4
Micro (n = 84)
No further involvement 69 82
1–3 nodes 10 12
4–9 nodes 3 4
[9 nodes 2 2
ITC (n = 33)
No further involvement 27 82
1–3 nodes 5 15
4–9 nodes 1 3
[9 nodes 0 0
a Further nodal involvement shown in correlation with the size of the
sentinel node metastases in the patients randomized to ALND arm.
ALND axillary lymph node dissection; Macro macrometastases
([2 mm); Micro micrometastases (0.2–2 mm); ITC isolated tumor
cells (\0.2 mm)
Technical Aspects and Outcome SNB 1859patients with micrometastases and isolated tumor cells in
the sentinel node, further nodal involvement was low
(18%) but not negligible. The ﬁnal analysis of the AMA-
ROS trial will show whether patients with a tumor-positive
sentinel node will be adequately treated with ART com-
pared to ALND in terms of axillary control and arm and
shoulder morbidity.
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